MILAN, 17 Jan (APM) - Fidia has formed a new strategic partnership with the Italian subsidiary of Novartis, this time for a group of ophthalmology and laryngology products, including two 'gold standard' topical eye therapies, Il Sole 24 Ore reported on Monday.
Carlo Pizzocaro, Fidia's CEO, described the deal as allowing the group to consolidate its position in the national and international ophthalmic markets and expand its portfolio of drugs. According to the agreement, Fidia's ophthalmology unit, Sooft Italia, will become the new sales channel for the products.
About Pharma's report on the deal on Monday noted that Fidia expanded in Spain last year after acquiring a group of ophthalmology products and regenerative medicines from Novartis (APMHE 64227
Pizzocaro was quoted as saying that the acquisition of Sooft Italia in 2017 led to Fidia reinforcing its expertise in ophthalmology, expanding the range of products for the treatment of eye diseases as well as building a number of important partnerships.
International expansion and the growth strategy are both being driven by the alliances. This has led to the creation of direct presences and subsidiaries in countries, such as Egypt and France, Pizzocaro said.
Former Mylan Italy CEO becomes country manager of Zentiva Italy
Mylan's former CEO in Italy has become country manager of Zentiva, Libero reported on Tuesday.
Cinzia Falasco Volpin has previously worked for companies such as Apple, Autogrill before moving into pharma 11 years ago. During her time as managing director of Mylan in Italy, she helped build the company into a leader in the generics market, the paper said.
She joined Zentiva a year after it was bought by Advent International. According to the paper, Zentiva Italy has set itself ambitious targets to develop its business so that it can become a trusted partner to pharmacies, achieve a high standard of customer engagement and make an effective contribution to the sustainability of the national health service.
"We are sure that Falasco Volpin's strategic vision coupled with her professionalism and proven experience, will contribute to the consolidation of a business model focused on the development and positioning of the company in the Italian market," Zentiva was quoted as saying.
Bologna research centre to focus on neurodegenerative diseases
A Bologna-based medical research centre is planning to focus more of its activities on neurodegenerative diseases and the search for effective therapies, Il Sole 24 Ore reported on Wednesday.
The Rita Levi-Montalcini Tecnopolo complex has just completed a significant expansion with one of the aims being to identify better development pathways.
The paper said that the recent failures of costly Phase III trials of drugs for dementia have highlighted the need for a new model based on a longer preclinical stages. It is hoped that this will lead to more efficient R&D with shorter development times and help identify new targets for treating neurodegenerative diseases.
The centre's recent achievements include deciphering a molecular mechanism underlying the failure to repair myelin in inflammatory diseases of the central nervous system and using artificial intelligence tools for early identification of cognitive decline based on the analysis of spontaneous language, the paper said.
HPV vaccine shortages in Turin mean thousands risk missing vaccination
Thousands of young people are at risk of missing out on HPV vaccinations in Turin because of shortages of vaccine, according to Thursday's La Repubblica.
The regions only supplier of the vaccine - which was not named in the article - has had production problems which led to supplies being halted in October last year, the paper said. Despite rationing the doses of vaccines they had in stock, some health bodies have now run out completely.
There are at least 32,000 boys and girls who are vaccinated every year in Turin. Some have had the first dose of HPV vaccine but not the second. Others have not been vaccinated at all, the paper said.
Chiesi completes acquisition of iron chelator deferiprone rights from Apotex
Chiesi has completed the acquisition of the worldwide rights to Apotex's iron chelator deferiprone, About Pharma reported on Tuesday.
The Parma-based group previously marketed the drug in Italy, Brazil and Turkey before agreeing to acquire the product last November.
Deferiprone is used to treat patients with thalassemia who have transfusional iron overload. Thalassemia is a group of rare hereditary haematological conditions which include beta thalassemia.
The deal will see around 50 employees from Apotex passing to Chiesi, allowing the Italian group to open offices in Toronto in Canada, the paper said.
Michael Spino, president of Chiesi Canada, said the two companies have already had more than 20 years of successful collaboration on this drug. "The ApoPharma team will strengthen Chiesi's plan for the development of this drug in the rare diseases area," he said.